Safety of rapid-acting insulin analogs versus regular human insulin.

Abstract

Insulin is the most effective treatment for both type 1 and type 2 diabetes mellitus. There are several differences in the safety profiles of each type of insulin, including rapid-acting insulin analogs and regular human insulin. The pharmacokinetic and pharmacodynamic properties of those insulin types also differ, as do their safety parameters. Treatment with rapid-acting analogs results in less hypoglycemia overall and decreased frequency of both severe and nocturnal hypoglycemia. In addition, the more rapid onset and shorter duration of action of rapid-acting insulin analogs are associated with greater control of postprandial glucose than regular human insulin. This review will describe the similarities and differences between the safety profiles of rapid-acting insulin analogs.

• Authors: Abbas E Kitabchi, Aidar R Gosmanov
• Journal: The American journal of the medical sciences (Am J Med Sci) Vol. 344 Issue 2 Pg. 136-41 (Aug 2012) ISSN: 1538-2990 [Electronic] United States
• PMID: 22270400 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Insulin, Short-Acting

Topics

• Humans
• Hyperglycemia (drug therapy)
• Hypoglycemia (chemically induced)
• Insulin, Short-Acting (adverse effects, pharmacokinetics)